JOP20170100B1 - توليف مركبات إندازول - Google Patents
توليف مركبات إندازولInfo
- Publication number
- JOP20170100B1 JOP20170100B1 JOP/2017/0100A JOP20170100A JOP20170100B1 JO P20170100 B1 JOP20170100 B1 JO P20170100B1 JO P20170100 A JOP20170100 A JO P20170100A JO P20170100 B1 JOP20170100 B1 JO P20170100B1
- Authority
- JO
- Jordan
- Prior art keywords
- indazoles
- synthesis
- intermediate compounds
- substituted indazole
- preparing
- Prior art date
Links
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- -1 2-substituted indazole Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/86—Hydrazides; Thio or imino analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
يتعلق الاختراع الحالي بطريقة جديدة لتحضير andnbsp;2-substituted indazole بالبنية التالية:
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16167652 | 2016-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20170100B1 true JOP20170100B1 (ar) | 2022-03-14 |
Family
ID=55860769
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2017/0100A JOP20170100B1 (ar) | 2016-04-29 | 2017-04-27 | توليف مركبات إندازول |
| JOP/2017/0099A JOP20170099B1 (ar) | 2016-04-29 | 2017-04-27 | شكل متعدد الأشكال من n-{6-(2-هيدروكسي بروبان-2-يل)-2-[2-(مثيل سلفونيل) إثيل]-2h-إندازول-5-يل}-6-(ثلاثي فلورومثيل) بيريدين-2-كربوكساميد |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2017/0099A JOP20170099B1 (ar) | 2016-04-29 | 2017-04-27 | شكل متعدد الأشكال من n-{6-(2-هيدروكسي بروبان-2-يل)-2-[2-(مثيل سلفونيل) إثيل]-2h-إندازول-5-يل}-6-(ثلاثي فلورومثيل) بيريدين-2-كربوكساميد |
Country Status (42)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| CA3016364A1 (en) | 2016-03-03 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs |
| SI3448846T1 (sl) | 2016-04-29 | 2021-09-30 | Bayer Pharma Aktiengesellschaft | Sinteza indazolov |
| CU24593B1 (es) | 2016-04-29 | 2022-05-11 | Bayer Pharma AG | Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)- piridin-2-carboxamida |
| MY199070A (en) * | 2016-06-01 | 2023-10-12 | Bayer Pharma AG | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseaes in animals |
| SG11201810769QA (en) | 2016-06-01 | 2018-12-28 | Bayer Pharma AG | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| EP3816164B9 (en) | 2018-06-25 | 2024-07-10 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Isothiazolo[5,4-d]pyrimidine compound as irak4 inhibitor |
| TWI842978B (zh) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| CN110981903A (zh) * | 2019-11-28 | 2020-04-10 | 南京正济医药研究有限公司 | 一种艾日布林中间体化合物提高光学纯度的精制方法 |
| AU2021353004A1 (en) | 2020-09-30 | 2023-04-13 | Nobell Foods, Inc. | Recombinant milk proteins and food compositions comprising the same |
| US10947552B1 (en) | 2020-09-30 | 2021-03-16 | Alpine Roads, Inc. | Recombinant fusion proteins for producing milk proteins in plants |
| US10894812B1 (en) | 2020-09-30 | 2021-01-19 | Alpine Roads, Inc. | Recombinant milk proteins |
| CN114469979B (zh) * | 2021-12-15 | 2024-04-09 | 安徽贝克生物制药有限公司 | 一种核糖核苷类似物的药物组合物、吸入剂及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| WO2007091107A1 (en) | 2006-02-10 | 2007-08-16 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| EP2045253A4 (en) | 2006-06-29 | 2013-01-23 | Nissan Chemical Ind Ltd | alpha-amino acid derivative and pharmaceutical agent containing it as an active ingredient |
| CN101616910A (zh) | 2006-09-07 | 2009-12-30 | 比奥根艾迪克Ma公司 | 作为白细胞介素-1受体相关激酶调节剂的吲唑衍生物 |
| JP5620393B2 (ja) | 2009-10-09 | 2014-11-05 | 田辺三菱製薬株式会社 | 脳梗塞治療薬 |
| WO2011153588A1 (en) | 2010-06-10 | 2011-12-15 | Biota Scientific Management Pty Ltd | Viral polymerase inhibitors |
| ES2592713T3 (es) | 2010-12-20 | 2016-12-01 | Merck Serono S.A. | Derivados de indazolil-triazol como inhibidores de IRAK |
| WO2013106254A1 (en) | 2012-01-11 | 2013-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| WO2015067782A1 (en) | 2013-11-08 | 2015-05-14 | Iteos Therapeutics | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| US9126984B2 (en) * | 2013-11-08 | 2015-09-08 | Iteos Therapeutics | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| JP2017505337A (ja) * | 2014-01-10 | 2017-02-16 | アウリジーン ディスカバリー テクノロジーズ リミテッド | Ｉｒａｋ４阻害剤としてのインダゾール化合物 |
| JO3705B1 (ar) * | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| EP3288558B1 (en) | 2015-04-30 | 2022-05-11 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| EA201890307A1 (ru) | 2015-07-15 | 2018-10-31 | Ориджин Дискавери Текнолоджиз Лимитед | Индазольные и азаиндазольные соединения как ингибиторы irak-4 |
| CA3016364A1 (en) | 2016-03-03 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs |
| EP3219329A1 (en) | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
| CU24593B1 (es) | 2016-04-29 | 2022-05-11 | Bayer Pharma AG | Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)- piridin-2-carboxamida |
| SI3448846T1 (sl) | 2016-04-29 | 2021-09-30 | Bayer Pharma Aktiengesellschaft | Sinteza indazolov |
| MY199070A (en) | 2016-06-01 | 2023-10-12 | Bayer Pharma AG | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseaes in animals |
| SG11201810769QA (en) | 2016-06-01 | 2018-12-28 | Bayer Pharma AG | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases |
-
2017
- 2017-04-25 SI SI201730851T patent/SI3448846T1/sl unknown
- 2017-04-25 PT PT177185600T patent/PT3448848T/pt unknown
- 2017-04-25 ES ES17718558T patent/ES2883298T3/es active Active
- 2017-04-25 WO PCT/EP2017/059767 patent/WO2017186703A1/en active Application Filing
- 2017-04-25 MX MX2018013235A patent/MX2018013235A/es unknown
- 2017-04-25 LT LTEPPCT/EP2017/059767T patent/LT3448848T/lt unknown
- 2017-04-25 EP EP23189520.2A patent/EP4275755A3/en active Pending
- 2017-04-25 CU CU2018000131A patent/CU20180131A7/es unknown
- 2017-04-25 ES ES17718560T patent/ES2966772T3/es active Active
- 2017-04-25 UA UAA201811329A patent/UA123169C2/uk unknown
- 2017-04-25 FI FIEP17718560.0T patent/FI3448848T3/fi active
- 2017-04-25 PL PL17718558T patent/PL3448846T3/pl unknown
- 2017-04-25 AU AU2017257211A patent/AU2017257211B2/en active Active
- 2017-04-25 DK DK17718560.0T patent/DK3448848T3/da active
- 2017-04-25 US US16/097,067 patent/US10759758B2/en active Active
- 2017-04-25 MX MX2018013234A patent/MX2018013234A/es unknown
- 2017-04-25 SG SG11201808108XA patent/SG11201808108XA/en unknown
- 2017-04-25 JP JP2018556408A patent/JP6954924B2/ja active Active
- 2017-04-25 HR HRP20231454TT patent/HRP20231454T1/hr unknown
- 2017-04-25 UA UAA201811516A patent/UA124103C2/uk unknown
- 2017-04-25 JP JP2018556409A patent/JP7068188B2/ja active Active
- 2017-04-25 RS RS20210898A patent/RS62112B1/sr unknown
- 2017-04-25 SI SI201731443T patent/SI3448848T1/sl unknown
- 2017-04-25 MY MYPI2018703965A patent/MY190319A/en unknown
- 2017-04-25 MA MA44759A patent/MA44759B1/fr unknown
- 2017-04-25 MY MYPI2018703968A patent/MY187184A/en unknown
- 2017-04-25 WO PCT/EP2017/059744 patent/WO2017186689A1/en active Application Filing
- 2017-04-25 EP EP17718558.4A patent/EP3448846B1/en active Active
- 2017-04-25 KR KR1020187030699A patent/KR102373017B1/ko active IP Right Grant
- 2017-04-25 GE GEAP201714933A patent/GEP20217214B/en unknown
- 2017-04-25 PL PL17718560.0T patent/PL3448848T3/pl unknown
- 2017-04-25 EP EP17718560.0A patent/EP3448848B1/en active Active
- 2017-04-25 EP EP23189176.3A patent/EP4275754A3/en not_active Ceased
- 2017-04-25 US US16/097,065 patent/US10501417B2/en active Active
- 2017-04-25 AU AU2017256626A patent/AU2017256626B2/en active Active
- 2017-04-25 SG SG11201808566WA patent/SG11201808566WA/en unknown
- 2017-04-25 HU HUE17718558A patent/HUE056460T2/hu unknown
- 2017-04-25 KR KR1020187030698A patent/KR102373220B1/ko active IP Right Grant
- 2017-04-25 CN CN201780040919.5A patent/CN109415340B/zh active Active
- 2017-04-25 IL IL262414A patent/IL262414B2/en unknown
- 2017-04-25 RS RS20231171A patent/RS64928B1/sr unknown
- 2017-04-25 TN TNP/2018/000352A patent/TN2018000352A1/en unknown
- 2017-04-25 LT LTEP17718558.4T patent/LT3448846T/lt unknown
- 2017-04-25 CA CA3022324A patent/CA3022324A1/en active Pending
- 2017-04-25 CN CN201780026130.4A patent/CN109071489B/zh active Active
- 2017-04-25 EA EA201892415A patent/EA201892415A1/ru unknown
- 2017-04-25 PE PE2018002251A patent/PE20190107A1/es unknown
- 2017-04-25 HU HUE17718560A patent/HUE064389T2/hu unknown
- 2017-04-25 CA CA3022332A patent/CA3022332A1/en active Pending
- 2017-04-25 EA EA201892430A patent/EA038035B1/ru unknown
- 2017-04-25 DK DK17718558.4T patent/DK3448846T3/da active
- 2017-04-25 CN CN202110343286.3A patent/CN113185457A/zh active Pending
- 2017-04-25 PT PT177185584T patent/PT3448846T/pt unknown
- 2017-04-27 JO JOP/2017/0100A patent/JOP20170100B1/ar active
- 2017-04-27 JO JOP/2017/0099A patent/JOP20170099B1/ar active
- 2017-04-28 TW TW106114178A patent/TWI657084B/zh active
- 2017-04-28 UY UY0001037215A patent/UY37215A/es not_active Application Discontinuation
- 2017-04-28 UY UY0001037216A patent/UY37216A/es active IP Right Grant
- 2017-04-28 AR ARP170101088A patent/AR108245A1/es unknown
- 2017-04-28 TW TW106114180A patent/TWI649314B/zh active
-
2018
- 2018-10-26 PH PH12018502289A patent/PH12018502289B1/en unknown
- 2018-10-29 CO CONC2018/0011644A patent/CO2018011644A2/es unknown
- 2018-10-29 NI NI201800112A patent/NI201800112A/es unknown
- 2018-10-29 SV SV2018005775A patent/SV2018005775A/es unknown
- 2018-10-29 EC ECSENADI201881437A patent/ECSP18081437A/es unknown
- 2018-10-29 CL CL2018003088A patent/CL2018003088A1/es unknown
- 2018-10-29 CO CONC2018/0011622A patent/CO2018011622A2/es unknown
- 2018-10-29 DO DO2018000237A patent/DOP2018000237A/es unknown
- 2018-10-29 SA SA518400333A patent/SA518400333B1/ar unknown
- 2018-10-29 CL CL2018003087A patent/CL2018003087A1/es unknown
- 2018-10-29 IL IL262659A patent/IL262659B/en active IP Right Grant
- 2018-11-28 ZA ZA2018/08057A patent/ZA201808057B/en unknown
-
2021
- 2021-07-06 HR HRP20211072TT patent/HRP20211072T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20170100B1 (ar) | توليف مركبات إندازول | |
| JOP20170101B1 (ar) | توليف مركبات إندازول | |
| MX2016008085A (es) | Procedimiento para la preparacion de cetonas fenoxifenilicas sustituidas. | |
| PH12017500833A1 (en) | Synthesis of copanlisib and its dihydrochloride salt | |
| TW201613853A (en) | Synthesis of polycyclic-carbamoylpyridone compounds | |
| MX2017003131A (es) | Metodo para la preparacion de 2-alcoxi ciclohexanol. | |
| MX2022010755A (es) | Inhibidores de quinasa y usos de los mismos. | |
| JO3487B1 (ar) | تخليق كوبانليسيب وملح الدايهيدروكلوريد الخاص به | |
| MX345926B (es) | Nuevas composiciones, producción de las mismas y uso de las mismas para la producción de poliamidas coladas. | |
| MX2016010272A (es) | Derivado de indolona sustituido por pirrol, metodo de preparacion del mismo, composicion que comprende el mismo y uso del mismo. | |
| MX2017011389A (es) | Proceso para la preparacion de 3-cloro-2-vinilfenilsulfonatos. | |
| HK1232076A1 (zh) | 用於取代的 -芐基- 異噁唑- -基甲基 -吡唑- -基 咪唑烷- -二酮的合成的改進方法 | |
| MX2016015298A (es) | Inhibidores de nampt y metodos. | |
| EA201692246A1 (ru) | Способ получения 2,6-диметилбензохинона | |
| NZ721832A (en) | Solid forms of tenofovir | |
| GB2564185A (en) | Process for the preparation of derivatives of benzodioxole | |
| IN2014MU00495A (ar) | ||
| MY190171A (en) | Synthesis of indazoles | |
| MX2017005669A (es) | Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos. | |
| MX2017011388A (es) | Proceso para la preparacion de derivados de fenilisoxazolina sustituida. | |
| IN2014MU00070A (ar) |